Acadia Pharma (NASDAQ: ACAD) is said to be facing tough questions ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Trader Talk Trading Halts

Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid March 30, 2016 6:49 AM Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ETMarch 29, 2016 5:43 PM Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's DiseaseMarch 29, 2016 5:14 PM Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - BloombergMarch 29, 2016 3:37 PM Acadia Pharma (ACAD) adequately characterized the safety profile of NUPLAZID - FDA PanelMarch 29, 2016 3:19 PM Acadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA PanelMarch 29, 2016 2:55 PM Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID March 29, 2016 7:05 AM ACADIA Pharmaceuticals Stock Trading Halted TodayMarch 29, 2016 7:05 AM Acadia Pharma (ACAD) trading halted with news pendingMarch 29, 2016 7:00 AM